Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of the six pillars of lifestyle medicine on the biology of skin aging.

Frontiers in aging·2026
Same author

Older adults with advanced chronic illness and emergency department care: the hermeneutic stories of Bill, Edie and Nicole.

BMC geriatrics·2026
Same author

Homeodynamic Rejuvenation: an adaptive framework for resetting skin aging.

Frontiers in aging·2026
Same author

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Blood·2026
Same author

Factors Associated with Antiretroviral Therapy Re-Engagement Among Men Who Have Sex with Men in South Africa: A Multi-District Analysis.

Viruses·2026
Same author

Biological Photoprotection: A Review of its Mechanisms, Evidence, and Clinical Implications.

Dermatology and therapy·2026

Related Experiment Video

Updated: Jul 19, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K

Ex vivo Drug Sensitivity Imaging-based Platform for Primary Acute Lymphoblastic Leukemia Cells.

Lauren Rowland1, Brandon Smart1, Anthony Brown1

  • 1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

Bio-Protocol
|August 14, 2023
PubMed
Summary

A new fluorescence imaging method rapidly tests acute lymphoblastic leukemia (ALL) cell drug sensitivity. This functional precision medicine approach identifies individual drug resistance and sensitivity patterns for better treatment strategies.

Keywords:
Acute lymphoblastic leukemiaEx vivo drug sensitivityFluorescence imagingFunctional precision medicinePharmacogenomicsPharmacotyping

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Author Spotlight: High-Throughput Screening of CAR T-Cell Constructs for Enhanced Cytotoxicity and Immunologic Memory
09:20

Author Spotlight: High-Throughput Screening of CAR T-Cell Constructs for Enhanced Cytotoxicity and Immunologic Memory

Published on: October 27, 2023

2.3K

Related Experiment Videos

Last Updated: Jul 19, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Author Spotlight: High-Throughput Screening of CAR T-Cell Constructs for Enhanced Cytotoxicity and Immunologic Memory
09:20

Author Spotlight: High-Throughput Screening of CAR T-Cell Constructs for Enhanced Cytotoxicity and Immunologic Memory

Published on: October 27, 2023

2.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Chemotherapy resistance in acute lymphoblastic leukemia (ALL) is a primary driver of treatment failure.
  • Current ex vivo drug sensitivity testing methods for ALL cells have significant limitations.
  • Primary ALL cells are available for testing at diagnosis or relapse.

Purpose of the Study:

  • To develop and validate a functional precision medicine method for ex vivo drug sensitivity testing of primary ALL cells.
  • To establish a high-throughput, automated assay for rapid pharmacotyping of leukemia cells.
  • To integrate drug sensitivity data with genomic profiling for genomics-guided precision medicine.

Main Methods:

  • Primary ALL cells from bone marrow aspirate or peripheral blood were co-cultured with mesenchymal stromal cells.
  • A fluorescence imaging platform was used to test drug sensitivity against a panel of 40 anti-leukemia drugs.
  • The assay involves 4 days of ex vivo culture, with 2-3 hours for sample preparation and 1.5 hours for imaging.

Main Results:

  • The developed assay automates data analysis, enabling high-throughput screening.
  • This method requires fewer cells and significantly reduces labor compared to previous ex vivo assays.
  • It provides individual drug resistance and sensitivity profiles (pharmacotypes) for primary ALL cells.

Conclusions:

  • This fluorescence imaging-based pharmacotyping assay offers an efficient and effective approach for ex vivo drug sensitivity testing in ALL.
  • The method addresses key limitations of existing assays, improving throughput and reducing hands-on time.
  • Integration with genomic data facilitates rational, genomics-guided precision medicine strategies for ALL treatment.